(URGN) UroGen Pharma Ltd. Business Model Canvas Research

UGN-102’s Phase III program depends on clinical trial sites, investigators, and patient-enrollment networks to run late-stage testing and generate registrational evidence. In cancer drug development, this kind of network is what turns a candidate into data the FDA can review.

• Phase III = pivotal late-stage testing
• Sites enable patient recruitment
• Investigators drive protocol execution
• Evidence supports regulatory approval

Urology and oncology specialists are essential partners because UroGen Pharma Ltd.’s therapies target specialized urinary tract diseases and cancers, where diagnosis, endoscopic delivery, and follow-up sit with these physicians. In 2025, Jelmyto remained the main commercial product, so specialist adoption directly supports prescribing and procedure-based use across the 90,000+ U.S. bladder cancer cases diagnosed each year.

• Drive diagnosis and patient selection
• Prescribe Jelmyto and pipeline drugs
• Perform procedure-based delivery

RTGel is UroGen Pharma Ltd.’s proprietary reverse thermal gelation polymer, and it is the core delivery tech behind therapies designed to boost local drug exposure and efficacy. The platform supports more than one candidate, including UroGen Pharma Ltd.’s approved JELMYTO and late-stage UGN-102, so platform progress directly drives pipeline value.

• RTGel is the delivery core.
• Supports multiple product candidates.
• Links platform progress to value.

Partnership management is a core operating task for UroGen Pharma Ltd.: it keeps 3 active relationships with Allergan, Agenus, and MD Anderson aligned across development, production, and commercialization. In 2025, this kind of execution mattered more as UroGen advanced its pipeline and commercial work, making partner coordination a continuing day-to-day function.

• 3 key partners to manage
• Covers development, production, commercialization
• Ongoing execution, not a one-time task

UGN-301 is UroGen Pharma Ltd.’s pipeline asset for high-grade non-muscle invasive bladder cancer, adding a new oncology program beyond its approved franchise. That matters because bladder cancer remains a large, recurring market and UGN-301 gives UroGen Pharma Ltd. another shot at long-term revenue growth and pipeline depth.

• Targets high-grade non-muscle invasive bladder cancer
• Extends the oncology pipeline
• Supports future growth potential

UroGen’s licensing and collaboration rights are core assets: 3 external agreements with Allergan, Agenus, and MD Anderson give it access to technology, development routes, and research support. These contractual rights help UroGen lower R&D risk and speed pipeline work without building every capability in-house.

• 3 key external agreements
• Access to technology
• Access to development pathways
• Research support from MD Anderson

Jelmyto is UroGen Pharma Ltd.’s approved commercial product, giving it an immediate revenue base in pyelocalyceal solutions for low-grade upper tract urothelial cancer. Its U.S. label covers adult patients and has already converted UroGen from a pure development story into a marketed-therapy company.

That matters because a single approved therapy can anchor sales, physician use, and payer access while UroGen expands its pipeline.

• Approved, marketed therapy
• Targets pyelocalyceal disease
• Creates direct commercial value

UroGen Pharma Ltd.’s value proposition is a pipeline built to meet unmet needs in non-muscle invasive bladder cancer (NMIBC). UGN-102 and UGN-301 extend the oncology pipeline across low-grade and high-grade NMIBC, giving the Company two shots at future treatment options.

• UGN-102 targets low-grade NMIBC
• UGN-301 targets high-grade NMIBC
• Two assets deepen oncology reach

UroGen Pharma Ltd. uses partner relationship management to run long-term agreements with external groups, and its Allergan, Agenus, and MD Anderson ties mean at least 3 active coordination lanes. This is a customer-facing governance task, not just admin, because deal terms, research work, and delivery timing all need tight control.

• 3 named partner relationships
• Long-term agreement management
• Structured partnership governance

UroGen Pharma Ltd. keeps patient-centered treatment support tight because it serves narrow clinical populations in specialized urinary tract cancer settings, so care is built around exact diagnosis, procedure timing, and symptom relief. That focused model supports outcome tracking and closer follow-up for patients who often have few options.

• Narrow populations, tailored care
• Specialized urinary tract cancer settings
• Outcome-led patient support

Allergan-related rights can widen UroGen Pharma Ltd. commercialization reach by tapping an established urology sales base, while Agenus partnership activity gives it external development and production routes that can speed scale-up without adding full in-house capacity. Partner channels lower launch friction and broaden market access.

• Allergan rights expand reach
• Agenus supports development and production
• Partners widen market access

UroGen Pharma Ltd. sells Jelmyto directly through its own commercial team, so the company controls pricing, field force activity, and physician outreach. That internal execution is the main engine for current revenue, because uptake depends on educating urologists and driving adoption in the office and hospital channel.

• Direct-to-physician sales model
• Internal education drives uptake
• Jelmyto is the core revenue source

Urologists are UroGen Pharma Ltd.'s core prescribers because they diagnose urinary tract disease, perform office procedures, and manage the full patient pathway. In practice, this means UroGen must win over a small, specialist audience that directly drives treatment choice and repeat use.

• Key prescribers for urinary tract care
• Guide diagnosis and procedures
• Control patient referral and treatment flow

Oncology centers and hospitals are core institutional customers for UroGen Pharma Ltd. Specialty cancer centers run trials, adopt new therapies fast, and deliver treatment at scale; MD Anderson, with more than 1.6 million patient visits a year, shows how major centers shape uptake. These buyers also drive referral flow and protocol use.

• Trial sites speed evidence generation
• Major centers influence adoption
• Hospitals support repeat treatment delivery

Sales and commercialization expense covers the commercial team, physician engagement, and launch prep for pipeline assets. For UroGen Pharma Ltd., this spend supports Jelmyto adoption and revenue growth, but it also lifts SG&A as the company builds its market reach.

• Commercial staff drive Jelmyto uptake.
• Physician outreach supports prescribing.
• Pipeline launch prep raises selling costs.

UroGen Pharma Ltd. carries licensing and collaboration costs tied to its agreements with Allergan, Agenus, and MD Anderson, which can mean upfront fees, milestone payments, shared development spend, and contract oversight. In 2025, these partnership obligations remained a core part of the Company Name’s cost base, alongside ongoing R&D spending.

• Fees and milestones can lift cash costs.

• Shared development spend adds variability.

• Contract management is a recurring overhead.

The Allergan agreement covers 2 product families, RTGel and clostridial toxin products, so UroGen Pharma Ltd can earn licensing income through upfront, milestone, and commercialization-linked payments. This is a partner-based stream, where revenue rises as Allergan advances rights and sales.

• 2 product families in scope
• Payments tied to rights
• Commercialization-linked income

UroGen Pharma Ltd. uses collaboration-related payments to help fund research and development, so partner cash can support pipeline progress before product sales scale. The Agenus and MD Anderson relationships add collaboration value by sharing development cost and risk, and this mattered in UroGen Pharma Ltd.’s 2025 funding mix.

• Partner payments help finance R&D.
• Agenus adds collaboration value.
• MD Anderson supports pipeline work.